Calton & Associates, Inc. Neurocrine Biosciences Inc Transaction History

Calton & Associates, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	SELL	$92.03 - $107.81 $4,877 - $5,713	-53 Reduced 2.33%	2,220 $235,000
Q2 2022 Jul 12, 2022	SELL	$75.79 - $100.07 $9,019 - $11,908	-119 Reduced 4.97%	2,273 $221,000
Q1 2022 Apr 12, 2022	BUY	$72.45 - $94.81 $173,300 - $226,785	2,392 New	2,392 $224,000
Q4 2021 Jan 13, 2022	SELL	$79.65 - $106.22 $180,247 - $240,375	-2,263 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$86.18 - $99.03 $1,551 - $1,782	-18 Reduced 0.79%	2,263 $217,000
Q2 2021 Aug 11, 2021	SELL	$89.43 - $102.27 $6,260 - $7,158	-70 Reduced 2.98%	2,281 $222,000
Q1 2021 May 03, 2021	SELL	$87.57 - $119.4 $87 - $119	-1 Reduced 0.04%	2,351 $229,000
Q4 2020 Jan 25, 2021	BUY	$86.91 - $108.33 $204,412 - $254,792	2,352 New	2,352 $225,000
Q3 2020 Oct 30, 2020	SELL	$96.16 - $135.15 $180,300 - $253,406	-1,875 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$85.09 - $130.36 $159,543 - $244,425	1,875 New	1,875 $229,000
Q1 2020 Apr 30, 2020	SELL	$75.11 - $113.76 $149,844 - $226,951	-1,995 Closed	0 $0
Q4 2019 Feb 03, 2020	BUY	$86.8 - $118.57 $173,166 - $236,547	1,995 New	1,995 $215,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.